These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9174181)

  • 1. Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640.
    Tanaka M; Hohmura M; Nishi T; Sato K; Hayakawa I
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1260-8. PubMed ID: 9174181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I.
    Ubukata K; Hikida M; Yoshida M; Nishiki K; Furukawa Y; Tashiro K; Konno M; Mitsuhashi S
    Antimicrob Agents Chemother; 1990 Jun; 34(6):994-1000. PubMed ID: 2203313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity of DV-7751a, a new fluoroquinolone.
    Tanaka M; Hoshino K; Ishida H; Sato K; Hayakawa I; Osada Y
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2112-8. PubMed ID: 8257132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of DU-6681a, an active form of the new oral carbapenem compound DZ-2640, in comparison with that of R-95867, faropenem and oral cephalosporins.
    Okuda J; Otsuki M; Oh T; Nishino T
    J Antimicrob Chemother; 2000 Jul; 46(1):101-8. PubMed ID: 10882697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria.
    Ueda Y; Sunagawa M
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2471-80. PubMed ID: 12878507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals.
    Fujimoto K; Takemoto K; Hatano K; Nakai T; Terashita S; Matsumoto M; Eriguchi Y; Eguchi K; Shimizudani T; Sato K; Kanazawa K; Sunagawa M; Ueda Y
    Antimicrob Agents Chemother; 2013 Feb; 57(2):697-707. PubMed ID: 23147735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
    Tanaka M; Yamazaki E; Chiba M; Yoshihara K; Akasaka T; Takemura M; Sato K
    Antimicrob Agents Chemother; 2002 Mar; 46(3):904-8. PubMed ID: 11850285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.
    Sato K; Hoshino K; Tanaka M; Hayakawa I; Osada Y
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1491-8. PubMed ID: 1324647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of sitafloxacin against clinical isolates in 2009].
    Amano A; Matsuzaki K; Kishi N; Saika T; Hasegawa M; Ikeda F; Matsumoto T; Yamaguchi H; Kanda Y; Shiozawa T
    Jpn J Antibiot; 2010 Dec; 63(6):411-30. PubMed ID: 21425595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
    Fritsche TR; Stilwell MG; Jones RN
    Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.
    Gales AC; Jones RN
    Diagn Microbiol Infect Dis; 2000 Jan; 36(1):19-36. PubMed ID: 10744364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
    Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN
    Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro antibacterial activity and beta-lactamase stability of SY5555, a new oral penem antibiotic.
    Inoue E; Mitsuhashi S
    Antimicrob Agents Chemother; 1994 Sep; 38(9):1974-9. PubMed ID: 7811005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of HSR-903, a new quinolone.
    Takahashi Y; Masuda N; Otsuki M; Miki M; Nishino T
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1326-30. PubMed ID: 9174193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem.
    Fukuoka T; Ohya S; Utsui Y; Domon H; Takenouchi T; Koga T; Masuda N; Kawada H; Kakuta M; Kubota M; Ishii C; Ishii C; Sakagawa E; Harasaki T; Hirasawa A; Abe T; Yasuda H; Iwata M; Kuwahara S
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2652-63. PubMed ID: 9420035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
    Biedenbach DJ; Beach ML; Jones RN
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.